BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

627 related articles for article (PubMed ID: 17525889)

  • 1. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T; Finazzi G
    Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Cancer J; 2007; 13(6):372-6. PubMed ID: 18032974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G; Barbui T
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G
    Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Front-line therapy in polycythemia vera and essential thrombocythemia.
    Barbui T; Finazzi MC; Finazzi G
    Blood Rev; 2012 Sep; 26(5):205-11. PubMed ID: 22784966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD).
    Murphy S
    Thromb Haemost; 1997 Jul; 78(1):622-6. PubMed ID: 9198227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G; Barbui T
    Leukemia; 2008 Aug; 22(8):1494-502. PubMed ID: 18596737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Essential thrombocythemia.
    Finazzi G; Harrison C
    Semin Hematol; 2005 Oct; 42(4):230-8. PubMed ID: 16210036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
    Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
    Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
    De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
    Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual Clinical Updates in Hematological Malignancies: a continuing medical education series: polycythemia vera and essential thrombocythemia: 2011 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2011 Mar; 86(3):292-301. PubMed ID: 21351120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera and essential thrombocythemia: 2013 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2013 Jun; 88(6):507-16. PubMed ID: 23695894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
    Landolfi R; Di Gennaro L; Novarese L; Patrono C
    Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment options for essential thrombocythemia and polycythemia vera.
    Vannucchi AM; Guglielmelli P; Pieri L; Antonioli E; Bosi A
    Expert Rev Hematol; 2009 Feb; 2(1):41-55. PubMed ID: 21082994
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
    Landolfi R; Cipriani MC; Novarese L
    Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polycythemia vera and essential thrombocythemia in young patients.
    Frezzato M; Ruggeri M; Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):11-7. PubMed ID: 8039752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.